Pacira BioSciences' Accumulated Expenses rose 427.62% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 427.62%. This contributed to the annual value of $80.1 million for FY2024, which is 2472.02% up from last year.
Pacira BioSciences' Accumulated Expenses amounted to $79.6 million in Q3 2025, which was up 427.62% from $71.0 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Accumulated Expenses ranged from a high of $127.6 million in Q4 2021 and a low of $50.2 million during Q1 2021
Moreover, its 5-year median value for Accumulated Expenses was $71.0 million (2025), whereas its average is $72.2 million.
Per our database at Business Quant, Pacira BioSciences' Accumulated Expenses skyrocketed by 7972.07% in 2021 and then crashed by 2969.81% in 2023.
Over the past 5 years, Pacira BioSciences' Accumulated Expenses (Quarter) stood at $127.6 million in 2021, then decreased by 29.61% to $89.8 million in 2022, then decreased by 28.45% to $64.2 million in 2023, then increased by 24.72% to $80.1 million in 2024, then fell by 0.6% to $79.6 million in 2025.
Its Accumulated Expenses was $79.6 million in Q3 2025, compared to $71.0 million in Q2 2025 and $80.1 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value